Head-To-Head Analysis: Alseres Pharmaceuticals (OTCMKTS:ALSE) versus Aquestive Therapeutics (NASDAQ:AQST)

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Alseres Pharmaceuticals and Aquestive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Aquestive Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Aquestive Therapeutics	$44.54 million	11.75	-$83.78 million	($0.61)	-6.84

Alseres Pharmaceuticals has higher earnings, but lower revenue than Aquestive Therapeutics.

Institutional & Insider Ownership

32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.9% of Alseres Pharmaceuticals shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Alseres Pharmaceuticals and Aquestive Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Aquestive Therapeutics	1	0	5	2	3.00

Aquestive Therapeutics has a consensus target price of $8.80, suggesting a potential upside of 111.03%. Given Aquestive Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Alseres Pharmaceuticals.

Summary

Aquestive Therapeutics beats Alseres Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.